CFTR and cystic fibrosis: In combination with CFTR correctors, which traffic F508del‐CFTR to the plasma membrane, ivacaftor also has clinical benefit for cystic fibrosis patients with the predominant F508del variant (e.g., Heijerman et al., 2019; Middleton et al., 2019).